Nearly 2,000 drug manufacturing plants are overdue for FDA inspections after COVID delays, AP finds
Federal regulators responsible for the safety of the U.S. drug supply are still struggling to get back to where they were in 2019, before the COVID-19 pandemic upended factory inspections in the U.S. and across the world, The Associated Press has found....
![](https://kbin.life/media/cache/resolve/entry_thumb/4e/a7/4ea72d12459e4b54180f3c539f39b9e5f1242d1b71dd0ca03d68f474f369ac11.jpg)